Company / Operating Income
ALNYLAM PHARMACEUTICALS, INC. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$501.6M
FY2025
5-year range
-$939.4M / $501.6M
FY2021-FY2025
Trend
+383.6%
vs FY2024
Sector context
#15 of 204
Health Care
What the data says
Operating Income changed +384% YoY in FY2025, a notable deviation from the 9-year average annual change of +44%.
Based on SEC 10-K filings.
$502M in FY2025. Top quartile in the Health Care sector.
Improved from -$282M to $502M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 204This company $501.6M Sector average $107.8M
▼
+365.5% above sector average
Key checks
Key Insights
- ALNYLAM PHARMACEUTICALS, INC.'s operating income has grown for 4 consecutive years.
- In FY2025, operating income increased 383.6% year-over-year.
- Ranks #15 out of 204 companies in the Health Care sector.
- Lowest operating income in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $501.6M | +383.6% |
| FY2024 | -$176.9M | +37.3% |
| FY2023 | -$282.2M | +65.9% |
| FY2022 | -$828.4M | +11.8% |
| FY2021 | -$939.4M | -15.3% |
| FY2020 | -$814.7M | -62.9% |
| FY2019 | -$500.1M | -17.8% |
| FY2018 | -$424.6M | +15.1% |
| FY2017 | -$500.1M | -17.8% |
| FY2016 | -$424.6M | -43.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026